Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cadonilimab plus lenvatinib and TACE in unresectable non-metastatic hepatocellular carcinoma
CTR20220702Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jul 2022
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Jul 2022; status: active.
02
Drugs
cadonilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20220702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220702.